| Filed On | Filing |
|---|---|
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | SCHEDULE 13G |
| 03 Nov 2026 |
Form 4: Chevallard Daniel R., Chief Financial Officer
Granted 652,063 Stock Option (right to buy) |
| 03 Nov 2026 | 10-Q |
| 02 Nov 2026 | SCHEDULE 13D/A |
| 02 Nov 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others
Sold 2,718,684 shares ($9.13M) |
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +1 more
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession |
| 27 Oct 2026 | SCHEDULE 13G |
| 21 Oct 2026 | SCHEDULE 13G/A |
| 08 Sep 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements |
| 02 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 30, 2026, Zach Scheiner notified LENZ Therapeutics, Inc. a Delaware corporation (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and from all committees of the Board on which he ser... |
| 26 Jun 2026 | SCHEDULE 13G |
| 15 Jun 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others
Granted 22,100 Stock Option (right to buy) |
| 15 Jun 2026 |
Form 4: George Jeffrey P., Director
Granted 22,100 Stock Option (right to buy) |
| 15 Jun 2026 |
Form 4: Drapkin Kimberlee C, Director
Granted 22,100 Stock Option (right to buy) |
| 15 Jun 2026 |
Form 4: Mccollum James W, Director
Granted 22,100 Stock Option (right to buy) |
| 15 Jun 2026 |
Form 4: Thunen Shelley B, Director
Granted 22,100 Stock Option (right to buy) |
| 15 Jun 2026 |
Form 4: Guerard Frederic, Director
Granted 22,100 Stock Option (right to buy) |
Loading...